Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors
The metabolism of tumors and immune cells in the tumor microenvironment (TME) can affect the fate of cancer and immune responses. Metabolic reprogramming can occur following the activation of metabolic-related signaling pathways, such as phosphoinositide 3-kinases (PI3Ks) and the mammalian target of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/7/2043 |
| _version_ | 1797608283569127424 |
|---|---|
| author | Min Chen Huanrong Lan Shiya Yao Ketao Jin Yun Chen |
| author_facet | Min Chen Huanrong Lan Shiya Yao Ketao Jin Yun Chen |
| author_sort | Min Chen |
| collection | DOAJ |
| description | The metabolism of tumors and immune cells in the tumor microenvironment (TME) can affect the fate of cancer and immune responses. Metabolic reprogramming can occur following the activation of metabolic-related signaling pathways, such as phosphoinositide 3-kinases (PI3Ks) and the mammalian target of rapamycin (mTOR). Moreover, various tumor-derived immunosuppressive metabolites following metabolic reprogramming also affect antitumor immune responses. Evidence shows that intervention in the metabolic pathways of tumors or immune cells can be an attractive and novel treatment option for cancer. For instance, administrating inhibitors of various signaling pathways, such as phosphoinositide 3-kinases (PI3Ks), can improve T cell-mediated antitumor immune responses. However, dual pathway inhibitors can significantly suppress tumor growth more than they inhibit each pathway separately. This review discusses the latest metabolic interventions by dual pathway inhibitors as well as the advantages and disadvantages of this therapeutic approach. |
| first_indexed | 2024-03-11T05:41:19Z |
| format | Article |
| id | doaj.art-d43d53569ae74f3bb7e08a359d964b8b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T05:41:19Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d43d53569ae74f3bb7e08a359d964b8b2023-11-17T16:25:14ZengMDPI AGCancers2072-66942023-03-01157204310.3390/cancers15072043Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway InhibitorsMin Chen0Huanrong Lan1Shiya Yao2Ketao Jin3Yun Chen4Department of Colorectal Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, ChinaDepartment of Surgical Oncology, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou 310002, ChinaDepartment of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, ChinaDepartment of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, ChinaDepartment of Colorectal Surgery, Xinchang People’s Hospital, Affiliated Xinchang Hospital, Wenzhou Medical University, Xinchang 312500, ChinaThe metabolism of tumors and immune cells in the tumor microenvironment (TME) can affect the fate of cancer and immune responses. Metabolic reprogramming can occur following the activation of metabolic-related signaling pathways, such as phosphoinositide 3-kinases (PI3Ks) and the mammalian target of rapamycin (mTOR). Moreover, various tumor-derived immunosuppressive metabolites following metabolic reprogramming also affect antitumor immune responses. Evidence shows that intervention in the metabolic pathways of tumors or immune cells can be an attractive and novel treatment option for cancer. For instance, administrating inhibitors of various signaling pathways, such as phosphoinositide 3-kinases (PI3Ks), can improve T cell-mediated antitumor immune responses. However, dual pathway inhibitors can significantly suppress tumor growth more than they inhibit each pathway separately. This review discusses the latest metabolic interventions by dual pathway inhibitors as well as the advantages and disadvantages of this therapeutic approach.https://www.mdpi.com/2072-6694/15/7/2043metabolic interventiondual inhibitormetabolic reprogrammingcancer therapy |
| spellingShingle | Min Chen Huanrong Lan Shiya Yao Ketao Jin Yun Chen Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors Cancers metabolic intervention dual inhibitor metabolic reprogramming cancer therapy |
| title | Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors |
| title_full | Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors |
| title_fullStr | Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors |
| title_full_unstemmed | Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors |
| title_short | Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors |
| title_sort | metabolic interventions in tumor immunity focus on dual pathway inhibitors |
| topic | metabolic intervention dual inhibitor metabolic reprogramming cancer therapy |
| url | https://www.mdpi.com/2072-6694/15/7/2043 |
| work_keys_str_mv | AT minchen metabolicinterventionsintumorimmunityfocusondualpathwayinhibitors AT huanronglan metabolicinterventionsintumorimmunityfocusondualpathwayinhibitors AT shiyayao metabolicinterventionsintumorimmunityfocusondualpathwayinhibitors AT ketaojin metabolicinterventionsintumorimmunityfocusondualpathwayinhibitors AT yunchen metabolicinterventionsintumorimmunityfocusondualpathwayinhibitors |